Best Cyclotron Systems Announces Successful Factory Acceptance Testing of 70-MeV High-Current Cyclotron for Delivery to Taiwan

Skip to Content News Archives Economy Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeBusiness Wire News ReleasesPMN Press ReleasesThis section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Best Cyclotron Systems Announces Successful Factory Acceptance Testing of 70-MeV High-Current Cyclotron for Delivery to TaiwanAuthor of the article:THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountOTTAWA, Ontario — Best Cyclotron Systems (BCS), a TeamBest Global (TBG) company with locations in Ottawa and Vancouver, Canada, and Knoxville, Tennessee, USA, is pleased to announce the successful completion in July of Factory Acceptance Tests (FAT) for the Best 70-MeV high-current proton cyclotron (B-70), a state-of-the-art accelerator designed, developed, and manufactured by TeamBest engineers and scientists in Canada.The B-70 will be shipped to the National Atomic Research Institute (NARI) in Taoyuan City, Taiwan. Installation and project completion are expected in 2027.TBG’s technology portfolio spans 6 MeV research cyclotrons with high proton current to high-energy 70 MeV multi-particle systems. The B-70 underscores Best’s continued commitment to advancing high-current proton and multi-particle alpha/deuteron/proton (adp) cyclotron technology and expanding access to accelerator-based radioisotope production and research capabilities. BCS is currently manufacturing 10+ cyclotrons of various energies for global customers while expanding facilities across North America, Europe, and India. BCS has manufactured and installed nearly 40 advanced medical cyclotrons and expects to produce more than ten cyclotrons annually beginning next year, contributing to production of radioisotopes for nuclear medicine and radiotherapy, as well as neutron production and fundamental particle research.Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againRecently, BCS celebrated the 16th anniversary of winning its first international tender for a high-current proton cyclotron for INFN in Italy in 2010. In 2016, BCS commissioned the B-70 cyclotron at INFN Legnaro, Italy. Building on that success, Best ABT developed the BG-95 and B-11 cyclotrons, optimized for on-site production of PET tracers, including F-18, N-13, C-11, and Ga-68—crucial for imaging in cardiology, oncology, and neurology. Their compact, shielded designs allow seamless installation adjacent to clinical imaging suites, improving workflow and expanding patient access to cutting-edge diagnostics. TBG’s cyclotrons are engineered for the safe, high-yield production of essential radioisotopes, including Technetium-99m—a cornerstone of nuclear imaging—as well as emerging isotopes that enable targeted cancer therapies.BCS is also developing a 200 MeV variable-energy cyclotron proton therapy system for treating medical conditions such as pediatric, eye, head/neck, breast, lung, brain and pancreatic cancers, neurological/cardiovascular abnormalities and other medical ailments.In addition, Best Particle Therapy, Inc. has designed the Ion Rapid Cycling Medical Synchrotron (iRCMS) for protons, carbon, and heavier ions, offering cancer patients exceptional treatment flexibility. In comparison to slow-cycling synchrotrons and cyclotrons, the iRCMS is faster, lighter, more accurate, and compatible with proton, carbon, simple, and future modalities.Each week, Best ABT/Best Cyclotron supports the delivery of thousands of radiopharmaceutical doses worldwide, helping clinicians detect disease earlier and make more informed treatment decisions. Through a continued commitment to innovation, TBG has helped advance the field of nuclear medicine for nearly two decades. From pioneering cyclotron technologies to expanding particle capabilities to include alpha and deuteron production, TeamBest continues to push the boundaries of what is possible—advancing global health, strengthening technological excellence, and laying the foundation for the next generation of breakthroughs.View source version on businesswire.com: This advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.